111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
纳米生物技术在肝癌消融治疗中的应用进展
Authors Gao Z, Yao L, Wei X, Wang S, Cao W, Deng W, Li X, Zhang Z, Wang S, Zhang Y, Li M , Xie Y
Received 7 July 2025
Accepted for publication 4 December 2025
Published 15 December 2025 Volume 2025:20 Pages 15109—15133
DOI https://doi.org/10.2147/IJN.S551980
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Dongwoo Khang
Zixuan Gao,1,* Linmei Yao,1,* Xin Wei,1,* Shuojie Wang,1,* Weihua Cao,1 Wen Deng,1 Xinxin Li,1 Ziyu Zhang,1 Shiyu Wang,1 Yaqin Zhang,1 Minghui Li,1,2 Yao Xie1,2
1Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People’s Republic of China; 2Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing, 100015, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Minghui Li, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People’s Republic of China, Email wuhm2000@sina.com Yao Xie, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People’s Republic of China, Email xieyao00120184@sina.com
Abstract: Hepatocellular carcinoma (HCC) remains one of the most prevalent and lethal primary liver malignancies worldwide. Despite significant advances in surgical resection and local ablation therapies, challenges such as low early detection rates, high postoperative recurrence, and limited local tumor control persist in clinical practice. In recent years, the rapid advancement of nanobiotechnology has opened new avenues for precise diagnosis and personalized therapy of HCC. Owing to their excellent biocompatibility and functional tunability, various nanocarriers have been extensively explored in ablation-based treatments to achieve targeted drug delivery, controlled release, enhanced image guidance, and immune modulation. These innovations have substantially improved both the efficacy and safety of ablation therapies. This review focuses on recent progress in the application of nanobiotechnology to HCC ablation, systematically summarizing its mechanisms, innovative strategies, and future prospects across radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation (CRA), high-intensity ultrasound focused ablation (HIFU), irreversible electroporation (IRE) and photothermal therapy (PTT). This review aims to comprehensively summarize recent advances in the application of nanobiomaterials—biocompatible and functionally engineered nanomaterials—in ablation-based therapies for HCC, emphasizing their roles in enhancing therapeutic efficacy, imaging guidance, and immune modulation.
Keywords: hepatic carcinoma, nanobiotechnology, ablation
1Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People’s Republic of China; 2Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing, 100015, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Minghui Li, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People’s Republic of China, Email wuhm2000@sina.com Yao Xie, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People’s Republic of China, Email xieyao00120184@sina.com
Abstract: Hepatocellular carcinoma (HCC) remains one of the most prevalent and lethal primary liver malignancies worldwide. Despite significant advances in surgical resection and local ablation therapies, challenges such as low early detection rates, high postoperative recurrence, and limited local tumor control persist in clinical practice. In recent years, the rapid advancement of nanobiotechnology has opened new avenues for precise diagnosis and personalized therapy of HCC. Owing to their excellent biocompatibility and functional tunability, various nanocarriers have been extensively explored in ablation-based treatments to achieve targeted drug delivery, controlled release, enhanced image guidance, and immune modulation. These innovations have substantially improved both the efficacy and safety of ablation therapies. This review focuses on recent progress in the application of nanobiotechnology to HCC ablation, systematically summarizing its mechanisms, innovative strategies, and future prospects across radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation (CRA), high-intensity ultrasound focused ablation (HIFU), irreversible electroporation (IRE) and photothermal therapy (PTT). This review aims to comprehensively summarize recent advances in the application of nanobiomaterials—biocompatible and functionally engineered nanomaterials—in ablation-based therapies for HCC, emphasizing their roles in enhancing therapeutic efficacy, imaging guidance, and immune modulation.
Keywords: hepatic carcinoma, nanobiotechnology, ablation